ANXA3

ANXA3

A gene on chromosome 4q21.21 that encodes annexin 3, a calcium-dependent phospholipid-binding protein that plays a role in regulating cellular growth and signal transduction pathways. It inhibits phospholipase A2 and has anti-coagulant properties.
References in periodicals archive ?
The panel includes seven genes (ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1, and IL2RB) and is tested on RNA extracted from peripheral blood [86].
The differential expression of annexin A3 (ANXA3) plays a major role in tumorigenesis, drug resistance, and metastasis [7].
Correlation between ANXA3 Protein Expression and Clinicopathological Indexes.
Multivariate Cox analysis was performed with the variables including tumor size, TNM stage, the number of lymphatic metastases, oncology grade, molecular subtyping, ANXA3 expression, and other indexes (all with P values < 0.10 in univariate analyses).
The present study evaluated the potential of ANXA3 as a biomarker for breast cancer.
ANXA3 plays a significant role in tumorigenesis, resistance to chemotherapeutics, and subsequent metastasis [3].
In the current study, differential expression of ANXA3 in different subtypes of breast cancer was detected by immunohistochemistry.
In the present study, we showed that the expression of ANXA3 was not correlated with the expressions of ER, PR, HER-2, and Ki-67.
The expression of ANXA3 is reported as an independent factor in the prognosis of prostate cancer and other cancers [11].
Biomolecular markers of outcome prediction in prostate cancer include PCA3, TMPSS2, MMP-9, ANXA3, GSTP1, BRCA1, BRCA2, Mismatch Repair Genes, HOXB13, and HPC.
Preliminary research indentified six genes (ANXA3, CLEC4D, LMNB1, PRPG4, VNN1, and IL2RB) whose expression could meaningfully discriminate between blood samples provided by 116 patients with colorectal cancer and 127 control subjects.
Preliminary research identified six genes (ANXA3, CLEC4D, LMNB1, PRRG4, VNN1, and 1L2RB) whose expression could meaningfully discriminate between blood samples provided by 116 patients with colorectal cancer and 127 control subjects.